| 货号 | 2706/10 |
| 别名 | 3,4-Dihydro-3-methyl-4-oxoimidazo[5 |
| 供应商 | Tocris |
| 生物活性 | DNA methylating, chemotherapeutic agent. Displays antitumor activity against a board spectrum of tumors, including leukemias, lymphomas and solid tumors (IC50 = 5.0 μM for cytotoxicity against mouse TLX5 lymphoma cells). Induces autophagy in malignant glioma cells. Exhibits enhanced activity when used in combination with CHC (Cat No. 5029). |
| 运输条件 | Blue Ice |
| 存放说明 | Ambient |
| 纯度 | >99 % |
| 计算分子量 | 194.15 |
| 分子式 | C6H6N6O2 |
| 可溶性/溶解性 | Soluble to 50 mM in DMSO |
| CAS号 | 85622-93-1 |
| 参考文献 | Kanzawaet al (2004) Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ. 11 448. PMID: 14713959. Bodellet al (2003) Formation of DNA adducts and induction of lacI mutations in big blue rat-2 cells treated with temozolomide: implications for the treatment of low-grade adult and pediatric tumors. Cancer Epidemiol.Biomarkers Prevent. 12545. Clarket al (1995) Antitumor imidazotetraazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide. J.Med.Chem. 38 1493. PMID: 7739008. Plowmanet al (1994) Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res. 54 3793. PMID: 8033099. |